Larimar Therapeutics

Historical price data

Larimar Therapeutics is a focused, clinical-stage biotechnology company dedicated to developing treatments for complex rare diseases, with an initial focus on Friedreich's ataxia. Its core achievement is the advancement of nomlabofusp (CTI-1601), a recombinant fusion protein designed to address the root cause of Friedreich's ataxia by delivering frataxin to mitochondria, now in Phase 2 development. The company's strategy leverages a proprietary intracellular delivery platform to create targeted protein replacement therapies, aiming to build a pipeline for monogenic rare diseases. Larimar went public in 2021 and operates as a lean organization concentrating resources on translating its platform into validated clinical outcomes.

Proprietary intracellular delivery platform designed to deliver functional proteins and other molecules to specific compartments inside cells, utilizing recombinant fusion proteins with cell-penetrating and subcellular targeting sequences.